Myovant Sciences (Myovant Sciences) Cash-to-Debt : 0.75 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Myovant Sciences's cash to debt ratio for the quarter that ended in Dec. 2022 was 0.75.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Myovant Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2022.

The historical rank and industry rank for Myovant Sciences's Cash-to-Debt or its related term are showing as below:

MYOV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.42 Med: 1.76 Max: No Debt
Current: 0.75

During the past 7 years, Myovant Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.42. And the median was 1.76.

MYOV's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.5 vs MYOV: 0.75

Myovant Sciences Cash-to-Debt Historical Data

The historical data trend for Myovant Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Myovant Sciences Cash-to-Debt Chart

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Cash-to-Debt

Get a 7-Day Free Trial

2.49

1.57

0.63

1.85

1.18

Myovant Sciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Cash-to-Debt	Get a 7-Day Free Trial															1.43	1.18	0.97	1.01	0.75

Competitive Comparison of Myovant Sciences's Cash-to-Debt

For the Biotechnology subindustry, Myovant Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myovant Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Cash-to-Debt falls into.

Myovant Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Myovant Sciences's Cash to Debt Ratio for the fiscal year that ended in Mar. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	434.187	/	(2.148	+	365.741)
	=	1.18

Myovant Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	274.437	/	(2.703	+	364.18)
	=	0.75

Myovant Sciences (NYSE:MYOV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Myovant Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek	director, officer: Principal Executive Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra	officer: Principal Financial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	officer: Principal Fin'l & Accounting	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo	director	ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957